LIGAND PHARMACEUTICALS INCORPORATED Payments To Acquire Equity Securities Fv Ni
LIGAND PHARMACEUTICALS INCORPORATED (LGNXZ) reported Payments To Acquire Equity Securities Fv Ni of $303.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-27.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireEquitySecuritiesFvNi · last filed 2026-02-27
- LIGAND PHARMACEUTICALS INCORPORATED payments to acquire equity securities fv ni for the quarter ending 2025-12-31 was $303.00K.
- LIGAND PHARMACEUTICALS INCORPORATED payments to acquire equity securities fv ni for the quarter ending 2024-12-31 was $0.00.
- LIGAND PHARMACEUTICALS INCORPORATED payments to acquire equity securities fv ni for the quarter ending 2023-12-31 was $0.00.
- LIGAND PHARMACEUTICALS INCORPORATED payments to acquire equity securities fv ni for fiscal 2025 was $303.00K, a 92.78% decline from fiscal 2024.
- LIGAND PHARMACEUTICALS INCORPORATED payments to acquire equity securities fv ni for fiscal 2024 was $4.20M.
- LIGAND PHARMACEUTICALS INCORPORATED payments to acquire equity securities fv ni for fiscal 2023 was $0.00.
- LIGAND PHARMACEUTICALS INCORPORATED payments to acquire equity securities fv ni for fiscal 2022 was $0.00.
| Period end | Payments To Acquire Equity Securities Fv Ni 3 month | Payments To Acquire Equity Securities Fv Ni 9 month | Payments To Acquire Equity Securities Fv Ni 12 month |
|---|---|---|---|
| 2025-12-31 | $303.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $303.00K 10-K · filed 2026-02-27 | |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-07 | ||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $4.20M 10-K · filed 2026-02-27 | |
| 2024-09-30 | $4.20M 10-Q · filed 2025-11-07 | ||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $0.00 10-K · filed 2026-02-27 | |
| 2023-09-30 | $0.00 10-Q · filed 2024-11-08 | ||
| 2022-12-31 | $0.00 10-K · filed 2025-02-28 |